✦ LIBER ✦

Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis

✍ Scribed by Sarah Konopelska; Tina Kienitz; Beverly Hughes; Matthias Pirlich; Jürgen Bauditz; Herbert Lochs; Christian J. Strasburger; Paul M. Stewart; Marcus Quinkler

Book ID: 108704232
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 184 KB
Volume: 70
Category: Article
ISSN: 0300-0664
DOI: 10.1111/j.1365-2265.2008.03358.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatic stellate cell activation in nona

Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver

✍ Kay Washington; Kelly Wright; Yu Shyr; Ellen B. Hunter; Sandy Olson; David S. Ra 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 350 KB

Hepatic gene expression in histologicall

Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis

✍ Raghavakaimal Sreekumar; Barbara Rosado; Deborah Rasmussen; Michael Charlton 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

Statins in Nonalcoholic Fatty Liver Dise

Statins in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Updated Review

✍ William Nseir, Mahmud Mahamid 📂 Article 📅 2013 🏛 Current Science Inc. 🌐 English ⚖ 182 KB

Nonalcoholic Fatty Liver Disease: Predic

Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese

✍ John B. Dixon; Prithi S. Bhathal; Paul E. O'Brien 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 269 KB

Insulin sensitizers in nonalcoholic fatt

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status

✍ Lance L. Stein; Mamie H. Dong; Rohit Loomba 📂 Article 📅 2009 🏛 Springer Healthcare Communications 🌐 English ⚖ 238 KB

Nonalcoholic fatty liver disease and non

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

✍ Raj Vuppalanchi; Naga Chalasani 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the western world. It is now recognized that these patients have myriad of important co-morbidities (e.g., diabetes, hypothyroidism and metabolic syndrome). The workup of patients with suspected NAFL